ArticleOncotarget2022

Correction: Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis.

Reza Bayat Mokhtari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.